Liquidity and Management's Plan	9 Months Ended
Jun. 30, 2023
Liquidity and Managements Plan [Abstract]
LIQUIDITY AND MANAGEMENT'S PLAN	2. LIQUIDITY AND MANAGEMENT’S PLAN The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company experienced negative cash flows from operations of $22,259,997 for the nine months ended June 30, 2023. As a result of the Company’s common stock offerings and common stock warrant exercises during the year ended September 30, 2021 and the registered direct offering in May 2023, the Company had working capital of approximately $35,323,293 at June 30, 2023. The Company estimates that its available cash resources will be sufficient to fund its operations through August 2024. The Company has generated no operating revenue to date and has principally raised capital through the issuance of debt and equity instruments to finance its operations. However, the Company’s continued operations beyond August 2024, including its development plans for Lymphir, Mino-Lok, Mino-Wrap, Halo-Lido and NoveCite, will depend on its ability to obtain regulatory approval to market Lymphir and/or Mino-Lok and generate substantial revenue from the sale of Lymphir and/or Mino-Lok and on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships, or out-licensing of its product candidates. However, the Company can provide no assurances on regulatory approval, commercialization, or future sales of Lymphir and/or Mino-Lok or that financing or strategic relationships will be available on acceptable terms, or at all. If the Company is unable to raise sufficient capital, find strategic partners or generate substantial revenue from the sale of Lymphir and/or Mino-Lok, there would be a material adverse effect on its business. Further, the Company expects in the future to incur additional expenses as it continues to develop its product candidates, including seeking regulatory approval, and protecting its intellectual property.

Liquidity and Management's Plan

9 Months Ended

Jun. 30, 2023

Liquidity and Managements Plan [Abstract]

2. LIQUIDITY AND MANAGEMENT’S PLAN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company experienced negative cash flows from operations of $22,259,997 for the nine months ended June 30, 2023. As a result of the Company’s common stock offerings and common stock warrant exercises during the year ended September 30, 2021 and the registered direct offering in May 2023, the Company had working capital of approximately $35,323,293 at June 30, 2023. The Company estimates that its available cash resources will be sufficient to fund its operations through August 2024.

The Company has generated no operating revenue to date and has principally raised capital through the issuance of debt and equity instruments to finance its operations. However, the Company’s continued operations beyond August 2024, including its development plans for Lymphir, Mino-Lok, Mino-Wrap, Halo-Lido and NoveCite, will depend on its ability to obtain regulatory approval to market Lymphir and/or Mino-Lok and generate substantial revenue from the sale of Lymphir and/or Mino-Lok and on its ability to raise additional capital through various potential sources, such as equity and/or debt financings, strategic relationships, or out-licensing of its product candidates. However, the Company can provide no assurances on regulatory approval, commercialization, or future sales of Lymphir and/or Mino-Lok or that financing or strategic relationships will be available on acceptable terms, or at all. If the Company is unable to raise sufficient capital, find strategic partners or generate substantial revenue from the sale of Lymphir and/or Mino-Lok, there would be a material adverse effect on its business. Further, the Company expects in the future to incur additional expenses as it continues to develop its product candidates, including seeking regulatory approval, and protecting its intellectual property.